What a16z Capital Management, L.L.C. reported holding on Form 13F for the quarter ended Sep 30, 2026.
CIK 1540358 · Filed Nov 16, 2026
Values are as the managers reported them, in dollars.Open the Form 13F on SEC EDGAR
| 28.2M |
| ±0% |
| $592.3M |
| 3% |
BRVEBraveheart Bio, Inc. | 10.2M | New | $206.7M | 1% |
RVMDRevolution Medicines, Inc. | 782.9K | −15.0% | $160.7M | 0.8% |
FRNMFreenome, Inc. | 5.6M | New | $87.8M | 0.4% |
LIMENeutron Holdings, Inc. | 2.8M | New | $80.3M | 0.4% |
XYZBlock, Inc. | 1M | ±0% | $74.8M | 0.4% |
SCTXScribe Therapeutics, Inc. | 3.1M | New | $56.7M | 0.3% |
FIGFigma, Inc. | 2.6M | −57.1% | $53.9M | 0.3% |
MAZEMaze Therapeutics, Inc. | 1.7M | ±0% | $46.3M | 0.2% |
STDNStandard Nuclear, Inc. | 2.9M | New | $34.5M | 0.2% |
DMRADamora Therapeutics, Inc. | 1.2M | ±0% | $26.3M | 0.1% |
BIOABioAge Labs, Inc. | 3.2M | ±0% | $22.9M | 0.1% |
ERASErasca, Inc. | 1.4M | −50.0% | $21M | 0.1% |
METAMeta Platforms, Inc. | 21K | −90.1% | $15.2M | 0.1% |
RBLXRoblox Corp | 274.6K | ±0% | $11.6M | 0.1% |
CAMPCamp4 Therapeutics Corp | 2.1M | ±0% | $8.6M | 0.1% |
AKTSAktis Oncology, Inc. | 415K | ±0% | $8.1M | 0.1% |
BTGOBitgo Holdings, Inc. | 666.4K | ±0% | $4.9M | 0.1% |
NAUTNautilus Biotechnology, Inc. | 2.7M | −70.7% | $3.8M | 0.1% |
BLSMBlossomHill Therapeutics, Inc. | 125K | New | $2.3M | 0.1% |
KLRAKailera Therapeutics, Inc. | 140K | ±0% | $1.6M | 0.1% |
DNAGinkgo Bioworks Holdings, Inc. | 108.6K | ±0% | $1.4M | 0.1% |
IPSTIP Strategy Holdings, Inc. | 4.1K | ±0% | $13.2K | 0.1% |